The import price scenario within the US market of Levocetirizine Dihydrochloride, one of the most active pharmaceutical ingredients of an antihistamine brand, has been observing a steady rise in prices at a mere 0.25% nominal increase, majorly on a CFR Los Angeles basis. Currently, the import price range has registered a considerable escalation from October to the end of 2025 owing to a series of reasons connected to tariffs, among other factors. Increased US tariffs on APIs imported from China and India, reaching as high as 20% for some products, have also pinched Levocetirizine Dihydrochloride margins, encouraging the increased consumption of the API due to the availability constraint. While tariff relief policies exist temporarily, uncertainty has continued to fuel the purchase of products in the forward market and the building of stocks. Slowdowns in Levocetirizine Dihydrochloride API manufacturing in Asia, together with the seasonality of allergy products, continue the trend of reduced supply and sustained prices.
